B · Normal
[Kelun Pharmaceutical Subsidiaries Announced Multiple Innovative Drug Research Results] On October 26th, Kelun Pharmaceutical issued an announcement that recently, the company’s holding subsidiary Sichuan Kelun Botai Biopharmaceutical Co., Ltd. A number of clinical research results were announced at the European Society for Medical Oncology (ESMO) conference, covering antibody drug conjugates (ADCs) targeting human trophoblast surface antigen 2 (TROP2), sac-TMT (Gately®) and ADCs targeting B7-H3. Data related to SKB500, including two studies of sac-TMT, were selected for the latest Breakthrough Abstract (LBA) oral presentation.
Futures Market Intelligence 🕐 2026-10-26 12:29
#cell #Futures Market Intelligence #TMT Industry Observation #medicine
Save as Image Generate a beautiful long image to share on Moments or in group chats Generate now ⬇
← Back to Telegraph

Related telegraphs

October 26th, Saudi government data showed that Saudi merchandise exports fell b 10-26 13:41 [Iran announced that officials from Saudi Arabia, Turkey, and Pakistan will visi 10-26 13:33 On October 26, South Africa’s minister stated that the long-term plan is to abol 10-26 13:30 On October 26, the Hang Seng Technology Index turned higher in the afternoon, wi 10-26 13:18 [Research: Some blood protein levels are related to the risk of prostate cancer] 10-26 13:15 On October 26, the Russian Ministry of Defense stated that Russian forces hit a 10-26 13:08

Comments

0/500
Captcha (click to refresh)
No comments yet